Ozempic vs Mounjaro — Which Is Better for Liver Health?

Ozempic (semaglutide) is a GLP-1 receptor agonist. It activates one receptor — GLP-1 — to produce its metabolic effects.

Mounjaro (tirzepatide) is a dual GLP-1 and GIP receptor agonist. It activates two receptors simultaneously — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism is the primary reason Mounjaro produces greater weight loss than Ozempic on average.

For liver health specifically, both GLP-1 and GIP receptors are expressed in liver tissue. The dual mechanism of Mounjaro may produce additive hepatic benefits compared to GLP-1 activation alone — though definitive head-to-head liver histology data comparing the two medications directly does not yet exist.

Weight loss is the primary driver of liver fat reduction on both medications, and liver fat reduction is the first step in MASLD improvement.

The phase 3b SURMOUNT-5 trial directly compared tirzepatide and semaglutide in patients with obesity, finding tirzepatide achieved an average of about 20% weight loss compared to about 14% for semaglutide at 72 weeks.

A 6% difference in average weight loss is clinically significant for liver health. MASLD research consistently shows that weight loss of 7–10% produces significant liver fat reduction, while weight loss of 10%+ is associated with MASH resolution in many patients. The greater the weight loss, the greater the expected liver benefit.

On this basis, Mounjaro would be expected to produce greater liver fat reduction on average than Ozempic at standard doses — because it produces more weight loss. This is consistent with early clinical data showing tirzepatide produces greater reductions in liver fat content than semaglutide in metabolic patients.

Ozempic and Wegovy (Semaglutide)

The evidence base for semaglutide and liver health is the most mature of any GLP-1 medication. The ESSENCE trial — phase 3, 800 participants, 72 weeks — demonstrated MASH resolution in 62.9% of patients on semaglutide 2.4mg versus 34.3% on placebo. The TGA provisionally approved Wegovy for MASH in April 2026 — the first GLP-1 with formal regulatory approval for liver disease in Australia.

Real-world data on standard-dose semaglutide (Ozempic 1mg) consistently shows liver enzyme improvement and liver fat reduction in patients with MASLD and type 2 diabetes, at lower magnitude than the higher Wegovy dose.

Mounjaro (Tirzepatide)

Phase 2 dedicated liver disease trial data shows tirzepatide produces significant reductions in liver fat content and liver enzyme levels — with effects broadly comparable to or exceeding those seen with semaglutide in phase 2 trials. In a dedicated clinical trial, after 52 weeks of treatment, over 62% of participants with a serious form of liver inflammation saw it resolve.

The SYNERGY-NASH phase 3 trial — the definitive liver disease data for tirzepatide — completed enrolment in 2025 with results expected in 2026.

This is the question most patients are asking — and the honest answer is that definitive head-to-head liver histology data does not yet exist.

What the data does support:

Semaglutide (Wegovy dose) has the more mature evidence base. Phase 3 MASH trial completed, published, and TGA-approved. If you have confirmed MASH and need the most evidence-supported treatment now, Wegovy is the only TGA-approved option for this indication.

Tirzepatide produces greater weight loss on average. Since weight loss drives liver fat reduction, greater weight loss is expected to produce greater liver benefit. If you respond better to tirzepatide for weight management, your liver may benefit more.

The mechanisms are complementary, not identical. Tirzepatide's additional GIP receptor activation adds metabolic effects that semaglutide alone does not provide. In theory, this may produce superior liver outcomes — but this has not been confirmed in completed phase 3 liver histology data.

For practical decision-making:

• Confirmed MASH at F2–F3, need treatment now: Wegovy is the TGA-approved choice
• Managing type 2 diabetes with MASLD and not yet at the MASH stage: either Ozempic or Mounjaro provides meaningful liver benefit
• Weight management primary goal with comorbid MASLD: Mounjaro may produce greater weight loss and therefore greater liver fat reduction — but awaiting SYNERGY-NASH data for definitive guidance
• Already on Mounjaro for weight management: your liver is likely benefiting; confirm with elastography and routine monitoring

Both medications are predominantly self-funded in Australia for most patients. Current approximate private costs:

• Ozempic: $120–$180/month (PBS subsidised for type 2 diabetes)
• Wegovy: $200–$400/month (private; PBS negotiations ongoing)
• Mounjaro: $200–$350/month (private prescription)

For patients with type 2 diabetes who also have MASLD, Ozempic may be the most accessible option given PBS subsidy. For patients who need MASH-specific treatment, Wegovy's new TGA indication may support a specialist case for subsidy under the MASH pathway.